CAR T – Cell Therapy Clinical Trials | A Drug Pipeline Analysis Report 2023 | Companies – Juno Pharma, Candle Pharma

CAR T – Cell Therapy Clinical Trials | A Drug Pipeline Analysis Report 2023 | Companies – Juno Pharma, Candle Pharma

June 07
14:13 2023
CAR T - Cell Therapy  Clinical Trials | A Drug Pipeline Analysis Report 2023 | Companies - Juno Pharma, Candle Pharma
DelveInsight Business Research LLP
(Nevada, Las Vegas) United States, DelveInsight’s “CAR T – Cell Therapy Competitive landscape, 2023,” report provides comprehensive insights about 250+ companies and 300+ drugs in the CAR T – Cell Therapy Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline

(Nevada, Las Vegas) United States, DelveInsight’s “CAR T – Cell Therapy Competitive landscape, 2023,” report provides comprehensive insights about 250+ companies and 300+ drugs in the CAR T – Cell Therapy Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the CAR T – Cell TherapyPipeline Report

  • Leading CAR T – Cell Therapy companies developing novel drug candidates are Candel Therapeutics, SillaJen Biotherapeutics, Wuhan Binhui Biotechnology, Virogin Biotech, Replimune, Istari Oncology, Immvira Pharma, Lokon Pharma, ORCA Therapeutics, Beijing SyngenTech, Tasly Pharmaceuticals, and many others

  • Promising CAR T – Cell Therapy pipeline therapies in various stages of development include BREYANZI, Valoctocogene Roxaparvovec, TILT-123, NG-347

CAR T – Cell Therapy Overview

CAR T – Cell Therapy is a technique that uses a gene(s) to treat, prevent or cure a disease or medical disorder. Often, CAR T – Cell Therapy works by adding new copies of a gene that is broken, or by replacing a defective or missing gene in a patient’s cells with a healthy version of that gene. Both inherited genetic diseases (e.g., hemophilia and sickle cell disease) and acquired disorders (e.g., leukemia) have been treated with CAR T – Cell Therapy. CAR T – Cell Therapy is the use of genetic material to treat or prevent disease. The genetic material that is delivered, DNA or RNA, has instructions to change how a protein—or group of proteins—is produced by the cell. For some diseases, this means making changes to account for too much, not enough, or incorrect essential proteins being produced within cells. This new genetic material, such as a working gene, is delivered into the cell using a vector. A vector is like a package used to deliver a specific message.

Discover more about the emerging CAR T – Cell Therapy drugs @ CAR T – Cell Therapy  Treatment Drugs

CAR T – Cell Therapy Pipeline Therapies and Key Companies

  • Juno Therapeutics: BREYANZI

  • BioMarin Pharmaceutical:  Valoctocogene Roxaparvovec

  • Candel Therapeutics: CAN-2409

  • CRISPR Therapeutics: CTX001

And many others.

Scope of the CAR T – Cell Therapy Pipeline Report 

  • Coverage: Global 

  • Key CAR T – Cell Therapy Companies: Candel Therapeutics, SillaJen Biotherapeutics, Wuhan Binhui Biotechnology, Virogin Biotech, Replimune, Istari Oncology, Immvira Pharma, Lokon Pharma, ORCA Therapeutics, Beijing SyngenTech, Tasly Pharmaceuticals and many others.

  • Key CAR T – Cell Therapy Pipeline Therapies: BREYANZI, Valoctocogene Roxaparvovec, CAN-2409,  CTX001, and many others.

Find out more about the CAR T – Cell Therapy treatment options in development @ CAR T – Cell Therapy  Clinical Trials

Table of Contents

1 Introduction

2Executive Summary

3CAR T – Cell Therapy: Overview

3.1 Introduction

3.2Mechanism of Action

3.3Application

3.4Limitation

3.5Approved Therapies

4CAR T – Cell Therapy-Analytical Perspective: In-depth Commercial Assessment

4.1CAR T – Cell Therapy Collaboration Analysis by Companies

Competitive Landscape

4.2Comparative Assessment of Companies (by therapy, development stage, and technology)

5Therapeutic Assessment

5.1Assessment by Product Type

5.2Assessment by Stage and Product Type

5.3Assessment by Route of Administration

5.4Assessment by Stage and Route of Administration

5.5Assessment by Molecule Type

5.6Assessment by Stage and Molecule Type

6CAR T – Cell Therapy: Company and Product Profiles (Marketed Therapies)

JW Therapeutics

6.1Company Overview

Relmacabtagene autoleucel

6.2Product Description

6.3Research and Development Activities

6.4Product Developmental Activities

7Oncolytic Virus Cancer Therapy: Company and Product Profiles (Pipeline Therapies)

7.1Late Stage Products (Registered)

7.2Comparative Analysis

CARsgen

7.3Company Overview

Zevorcabtagene autoleucel

7.4Product Description

7.5Research and Development Activities

7.6Product Developmental Activities

Drug profiles in the detailed report…..

8Mid Stage Products (Phase II)

8.1Comparative Analysis

Cartesian Therapeutics

8.2Company Overview

Descartes 011

8.3Product Description

8.4Research and Development Activities

8.5Product Developmental Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

  • Comparative Analysis

Autolus Therapeutics

  • Company Overview

AUTO-8

  • Product Description

  • Research and Development Activities

  • Product Developmental Activities

Drug profiles in the detailed report…..

Preclinical and Discovery Stage Products

  • Comparative Analysis

Sana Biotechnology

  • Company Overview

SG299

  • Product Description

  • Research and Development Activities

  • Product Developmental Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

CAR T – Cell Therapy – Unmet needs

CAR T – Cell Therapy– Market drivers and barriers

Appendix

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services